Annovis Bio Inc

NYSE ANVS

Data sourced from

and

Download Data

Annovis Bio Inc Free Cash Flow to Equity (FCFE) 3 year CAGR for the year ending September 20, 2024

Annovis Bio Inc Free Cash Flow to Equity (FCFE) 3 year CAGR is NA for the year ending September 20, 2024. Free Cash Flow to Equity represents the cash flow available to equity shareholders after accounting for capital expenditures and net acquisitions. It indicates the amount of cash flow that can be distributed to shareholders or reinvested in the business. It is useful in assessing the company's ability to generate cash flow for its equity investors. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NYSE: ANVS

Annovis Bio Inc

CEO	Dr. Maria L. Maccecchini Ph.D.
IPO Date	Feb. 12, 2010
Location	United States
Headquarters	1055 Westlakes Drive, Berwyn, PA, United States, 19312
Employees	6
Sector	Healthcare
Industry	Biotechnology

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key trends